KRYS.jpg
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
October 26, 2021 07:00 ET | Krystal Biotech, Inc.
Topline results anticipated in the fourth quarter of 2021Of the 31 patients enrolled in the trial, 29 patients completed the study with no missing visits, including the three primary endpoint...
InMed Pharmaceuticals Inc..jpg
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa
September 30, 2021 07:30 ET | InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Sept. 30, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare...
Logo.png
DelveInsight Highlights Major Advances, Transformative Therapies and Leading Players Wheeling the Dystrophic Epidermolysis Bullosa Pipeline Landscape
June 30, 2021 20:00 ET | DelveInsight Business Research LLP
Los Angeles, USA, June 30, 2021 (GLOBE NEWSWIRE) -- DelveInsight Highlights Major Advances, Transformative Therapies and Leading Players Wheeling the Dystrophic Epidermolysis Bullosa Pipeline...
InMed Pharmaceuticals Inc..jpg
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa
April 28, 2021 07:30 ET | InMed Pharmaceuticals Inc.
Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 creamAdditional submissions slated for France, Germany, Greece, and Italy over the next several days and...
Logo.png
Epidermolysis bullosa pipeline anticipated to offer several novel pipeline therapies in the next decade
January 12, 2021 12:00 ET | DelveInsight Business Research LLP
Los Angeles, USA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Epidermolysis bullosa pipeline anticipated to offer several novel pipeline therapies in the next decade  The Epidermolysis bullosa clinical...
logo.png
AMRYT RECEIVES POSITIVE OPINION FROM EMA ON ORPHAN DRUG DESIGNATION FOR AP103
September 15, 2020 07:00 ET | Amryt Pharma Plc
  AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT RECEIVES POSITIVE OPINION FROM EMA ON ORPHAN DRUG DESIGNATION FOR AP103 DUBLIN, Ireland, and Boston MA, September 15 2020,  Amryt (Nasdaq: AMYT,...
FINAL_eb7-2 (3).png
EB Research Partnership Announces New $3 Million Gift from the Ann & Ari Deshe Family
November 07, 2019 09:00 ET | EB Research Partnership
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), the largest 501(c)(3) nonprofit dedicated to funding research aimed at treating and ultimately curing Epidermolysis...
FINAL_eb7-2 (3).png
EB Research Partnership Announces the 3rd Annual Believe in Brady on April 7 in Houston
April 01, 2019 14:19 ET | EB Research Partnership
HOUSTON, April 01, 2019 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), the largest nonprofit dedicated to funding research aimed at treating and ultimately curing Epidermolysis Bullosa (EB), is...
FINAL_eb7-2 (3).png
ESPN’s Scott Van Pelt to Host 2nd Annual Change for Charley on March 9 in Chicago
March 01, 2019 09:30 ET | EB Research Partnership
CHICAGO, March 01, 2019 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), the largest nonprofit dedicated to funding research aimed at treating and ultimately curing the devastating and...
FINAL_eb7-2 (3).png
EB Research Partnership Announces the 2nd Annual Plunge for Elodie on March 2 in Wellesley
February 21, 2019 09:04 ET | EB Research Partnership
BOSTON, Feb. 21, 2019 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), the largest nonprofit dedicated to funding research aimed at treating and ultimately curing Epidermolysis Bullosa (EB), is...